Skip to main content

Day: August 5, 2025

Surgery Partners, Inc. Announces Second Quarter 2025 Results

Reaffirms Full Year 2025 Guidance BRENTWOOD, Tenn., Aug. 05, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights (All comparisons are year-over-year unless otherwise noted)Revenue increased 8.4% for the second quarterSame-facility revenues increased 5.1% for the second quarter Same-facility cases increased 3.4% for the second quarterNet loss attributable to Surgery Partners, Inc. was $2.5 million for the second quarterAdjusted EBITDA increased 9.0% to $129.0 million for the second quarter2025 GuidanceFull year 2025 revenue and Adjusted EBITDA guidance reaffirmed to be in the range of $3.30 billion to...

Continue reading

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 – – Cash runway into the second quarter of 2026 – BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and provided a corporate update. “The second quarter was a key inflection point for Sensei, as we now transition from early response-focused readouts to longer-term and commercially relevant efficacy signals with the maturity of the data from our Phase 1/2 study of solnerstotug,” said John Celebi, President and CEO of Sensei. “Solnerstotug has demonstrated a favorable safety profile and in combination with...

Continue reading

Smithfield’s “We Speak Pork” Campaign Features Pork So Good It Speaks for Itself

Creative platform designed to drive awareness among Gen Z and Millennials, expand Smithfield’s leadership in packaged meats segmentI sizzle, smoke, and crisp to perfection. So let me do the talking.Smithfield – We Speak PorkI basically invented the ham sandwich.Smithfield – We Speak PorkI can get crispy.Smithfield – We Speak PorkNow we’re talking.Smithfield – We Speak PorkI put on my best marinade for you.SMITHFIELD, Va., Aug. 05, 2025 (GLOBE NEWSWIRE) — Smithfield® has launched a new national advertising campaign, “We Speak Pork,” showcasing pork so good it speaks for itself. The video campaign features Emmy Award-winning writer, actor and comedian Ben Schwartz as the voice of Smithfield’s portfolio of products, including bacon, Prime Fresh...

Continue reading

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has received the clinical study report (CSR) for the trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-MS in Healthy Adult Participants.” The CSR concludes that there were no safety or tolerability concerns that were identified in healthy participants following treatment with consecutive daily dosing of Lucid-MS. Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique...

Continue reading

Hillman’s Board of Directors Approves $100 Million Share Repurchase Program

Share Repurchase Program is Hillman’s first since becoming public in 2021 CINCINNATI, Aug. 05, 2025 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, announced that its Board of Directors has authorized an initial share repurchase program (“SRP”) for up to $100 million of the Company’s outstanding common stock. This new authorization permits shares of common stock to be repurchased from time to time at management’s discretion, through a variety of methods, including a 10b5-1 trading plan, open market purchases, privately negotiated transactions or transactions otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. This is the first SRP that Hillman has implemented since becoming...

Continue reading

Sportradar Reports Second Quarter Financial Results and Raises Full Year 2025 Outlook

Second Quarter 2025 HighlightsRevenue increased 14% to a record €318 million Profit for the period increased to €49 million and expanded to 15.5% as a percentage of revenue Adjusted EBITDA1 increased 31% to €64 million and Adjusted EBITDA margin1 expanded to 20.1% Net cash generated from operating activities increased 14% to €97 million and Free cash flow1 was €52 million Achieved a Customer Net Retention Rate1 of 117% Repurchased $65.5 million of shares under the share repurchase plan Raised full year outlook to revenue of at least €1,278 million, or 16% growth and Adjusted EBITDA of at least €284 million, or 28% growth.ST. GALLEN, Switzerland, Aug. 05, 2025 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences...

Continue reading

J & J Snack Foods Reports Fiscal 2025 Third Quarter Results

MOUNT LAUREL, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — J & J Snack Foods Corp. (NASDAQ: JJSF) (the “Company”) today reported financial results for the third quarter ended June 28, 2025.     Third Quarter  Actuals $ vs. LY % vs. LYNet Sales $454.3M $14.3M 3%Gross Profit $150.0M $2.3M 2%Operating Income $60.6M $10.5M 21%Net Earnings $44.2M $7.9M 22%Earnings per Diluted Share $2.26 $0.39 21%       Adjusted Operating Income $53.4M $0.4M 1%Adjusted EBITDA $72.0M $1.2M 2%Adjusted Earnings per Diluted Share $2.00 $0.02 1%       This press release contains non-GAAP financial measures. Please refer to the Non-GAAP Financial Measures section below for reconciliations to the most comparable GAAP measures. Dan Fachner, J&J Snack Foods Chairman, President, and CEO stated, “We delivered strong...

Continue reading

Exodus Movement, Inc. July 2025 Treasury Update and Monthly Metrics

July MAUs reach 1.7 million; Treasury contains 2,087 BTC OMAHA, Neb., Aug. 05, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital asset holdings of Exodus’ corporate treasury, as well as updated user and exchange provider processed volume metrics, as of July 31, 2025: Selected Digital Asset Holdings (Unaudited)Bitcoin (BTC): 2,087 BTC as of July 31, 2025 compared to 2,058 as of June 30, 2025Ethereum (ETH): 2,742 ETH as of July 31, 2025 compared to 2,729 as of June 30, 2025Solana (SOL): 34,578 SOL as of July 31, 2025 compared to 31,823 as of June 30, 2025 UsersMonthly Active Users (MAUs): 1.7 million as of July 31, 2025, of which approximately 20,000 are Passkeys wallets. That...

Continue reading

Neuronetics Reports Second Quarter 2025 Financial and Operating Results

Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $5 million In August 2025, received an additional $10 million in funding under the existing debt agreement with Perceptive Advisors LLC MALVERN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2025. Second Quarter...

Continue reading

Xometry Reports Record Second Quarter 2025 Results

Q2 revenue increased 23% year-over-year to a record $163 million driven by robust marketplace growth. Q2 marketplace revenue increased 26% year-over-year driven by strong enterprise growth and expanding networks of buyers and suppliers. Q2 gross profit increased 23% year-over-year to a record $65.2 million, or 40.1% of revenue driven by record marketplace gross margin of 35.4%. Q2 Adjusted EBITDA improved $6.6 million year-over-year to Adjusted EBITDA of $3.9 million driven by expanding marketplace gross margin and strong operating expense leverage. Strong operating results are driven by consistent execution across growth initiatives: expanding buyer and supplier networks; driving deeper enterprise engagement; further expanding the marketplace platform; growing internationally and enhancing supplier services.NORTH BETHESDA, Md., Aug....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.